

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 December 2021 (09.12.2021)



(10) International Publication Number
WO 2021/244653 A1

(51) International Patent Classification:

C07K 14/725 (2006.01) *A61P 37/04* (2006.01)
A61K 38/00 (2006.01) *C12N 15/85* (2006.01)
A61K 38/17 (2006.01) *C07K 16/08* (2006.01)
A61K 48/00 (2006.01)

(21) International Application Number:

PCT/CN2021/098487

(22) International Filing Date:

04 June 2021 (04.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/094628

05 June 2020 (05.06.2020)

CN

(71) Applicants: **GUANGDONG TCRURE BIOPHARMA TECHNOLOGY CO., LTD.** [CN/CN]; Building 12, No. 6 Nanjiang Second Road, Zhujiang Avenue, Nansha District, Guangzhou, Guangdong 510000 (CN). **TCRURE BIOPHARMA CORP.** [US/US]; P.O. Box 2403, Chapel Hill, North Carolina 27515 (US).

(72) Inventors: **WU, Haiyang**; Building 12, No. 6 Nanjiang Second Road, Zhujiang Avenue, Nansha District, Guangzhou, Guangdong 510000 (CN). **ZHOU, Jie**; Building 12, No. 6 Nanjiang Second Road, Zhujiang Avenue, Nansha District, Guangzhou, Guangdong 510000 (CN). **DENG, Dachuan**; Building 12, No. 6 Nanjiang Second Road, Zhujiang Avenue, Nansha District, Guangzhou, Guangdong 510000 (CN). **LI, Si**; 28 E Linda Vista Ave, Alhambra, California 91801 (US). **ZHAO, Lixia**; 119 Parkarbor Ln, Cary, North Carolina 27519 (US). **ZHANG, Lu**; 4104 Liddington Drive, Durham, North Carolina 27705 (US). **CHEN, Rui**; 4104 Liddington Drive, Durham, North Carolina 27705 (US). **BRYSON, Paul**; 3442 Caroline Avenue, Culver City, California 90232 (US). **MUDGAL, Poorva Prakash**; 908 Avalon Drive, Mebane, North Carolina 27302 (US).

(74) Agent: **LINDA LIU & PARTNERS**; F16 Tower C, Beijing Global Trade Center, 36 North Third Ring East Road, Dongcheng District, Beijing 100013 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TCR-T CELL THERAPY TARGETING EPSTEIN-BARR VIRUS




FIG. 1

(57) Abstract: Provided are T cell receptors that recognize or bind to Epstein-Barr virus (EBV) antigens, genetically engineered cells, and cell-based therapies.



WO 2021/244653 A1